Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy.

Journal of translational medicine. 2024 Mar 03*** epublish ***

Sike He, Haoyang Liu, Junru Chen, Hao Zeng

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. , Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. ., Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/38433208